Georgiou N A, van der Bruggen T, Jansen C A, Oudshoorn M, Nottet H S, Marx J J, van Asbeck B S
Department of Internal Medicine, Room F02.126, University Medical Center Utrecht, Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.
Int J Antimicrob Agents. 2001 Dec;18(6):513-8. doi: 10.1016/s0924-8579(01)00453-8.
It has been suggested that the combination of cancer chemotherapy with antiviral therapy is helpful for the containment of lymphomas in HIV-infected patients. Since we have recently shown that the nucleic acid binding chemotherapeutic agent bleomycin in itself has antiviral properties, we looked to see if there was any possible synergy with current anti-HIV agents. Combinations of zidovudine, indinavir or ritonavir with bleomycin, synergistically inhibited HIV-1(AT) replication in stimulated peripheral blood lymphocytes (combination index at 50% virus inhibition was 0.427, 0.604 and 0.535, respectively) and this synergism was not accompanied by any synergistic effects on cytotoxicity. We conclude from these data that further studies to investigate the clinical efficacy of combinations of antiviral and cancer chemotherapeutic agents are warranted in relation to viral load improvement.
有人提出，癌症化疗与抗病毒疗法相结合有助于控制HIV感染患者的淋巴瘤。由于我们最近发现核酸结合化疗药物博来霉素本身具有抗病毒特性，因此我们研究了它与目前的抗HIV药物是否存在协同作用。齐多夫定、茚地那韦或利托那韦与博来霉素联合使用，可协同抑制刺激外周血淋巴细胞中HIV-1(AT)的复制（50%病毒抑制时的联合指数分别为0.427、0.604和0.535），且这种协同作用并未伴随对细胞毒性的任何协同效应。根据这些数据，我们得出结论，有必要进一步研究抗病毒药物与癌症化疗药物联合使用在改善病毒载量方面的临床疗效。
